pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 49 Non-oncology: 34
Oncology: 15
Under Consideration for Negotiation 17 Non-oncology: 10
Oncology: 7
Completed Negotiations 825 With Letter of Intent: 716
Without agreement: 109
Negotiations That Were Not Pursued 111

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Opdivo Bristol Myers Squibb Canada Inc. Multiple Indications
Omnipod 5 Insulet Canada Corporation Patients with Type 1 Diabetes aged 2 years and old
Camcevi Accord Healthcare Inc. For the treatment of adult patients with advanced prostate cancer
TBC Sandoz Canada Inc. Multiple Indications
Eydenzelt Celltrion Healthcare Canada Ltd. Multiple Indications
TBC (aflibercept) Organon Canada Inc. Multiple Indications
Yesafili Biocon Biologics Canada Inc. Multiple Indications
Pavblu Amgen Canada Inc. Multiple Indications
Aflivu Apotex Inc. Multiple Indications
Jemperli GlaxoSmithKline Inc. ​In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Abilify Asimtufii Otsuka Canada Pharmaceutical Inc. Schizophrenia
Casgevy Vertex Pharmaceuticals (Canada) Incorporated Sickle cell disease
Casgevy Vertex Pharmaceuticals (Canada) Incorporated Transfusion-dependent β-thalassemia
Noyada Ethypharm Inc. Multiple Indications

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia (non-familial and heterozygous familial)
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia
Balversa Janssen Inc. Adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior th
Bylvay Medison Pharma Canada Inc. Pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis (PFIC).
Vyloy Astellas Pharma Inc. In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal
Keytruda Merck Canada Inc. In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Crysvita Kyowa Kirin Canada, Inc. X-Linked Hypophosphatemia

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks